Find Academic Supervisors

• Lymphoma
• Hodgkin Lymphoma
• Non-Hodgkin Lymphoma
• +5 more

Jonathan W. Friedberg, M.D., M.M.Sc. is the Director of the Wilmot Cancer Institute and Professor in the Department of Medicine, Hematology/Oncology at the University of Rochester School of Medicine and Dentistry. He holds the Samuel E. Durand Chair in Medicine and leads one of the nation's premier lymphoma programs. Dr. Friedberg is internationally recognized for his expertise in lymphoma treatment, particularly in developing novel therapies and clinical trial approaches. Dr. Friedberg's research focuses on lymphoma, with particular expertise in Hodgkin lymphoma, non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, and chronic lymphocytic leukemia. His work spans the entire treatment continuum from diagnosis through novel therapies including autologous stem cell transplantation and CAR-T cell interventions. He has built a comprehensive lymphoma program with expertise spanning hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. His research interests include developing risk-adapted treatment strategies, investigating novel therapeutic agents, and improving outcomes for patients with various lymphoma subtypes. Dr. Friedberg's extensive publication record demonstrates his leadership in lymphoma research, with recent work focusing on immunotherapy combinations, predictive modeling, risk stratification, and novel treatment approaches for various lymphoma subtypes. His research has significantly contributed to the understanding and treatment of lymphomas, particularly in developing more personalized and effective treatment strategies. Scientific Awards: Faculty Academic Mentoring Award (2012) Scholar in Clinical Research (2008) America's Top Doctors Selection (2008) Jacob Gitelman Award (2007) Lawrence A. Kohn Senior Teaching Fellow (2004-2006) Clinical Investigator Career Development Award (2003) Clinical Oncology Research Fellowship "Immunotherapy of Hodgkin's Disease" (2001-2003) Rising stars program for innovative research (2001-2003) As Director of the Wilmot Cancer Institute, Dr. Friedberg leads numerous clinical trials and research initiatives focused on advancing lymphoma treatment. He is actively involved in SWOG and has served in leadership roles for multiple clinical trials investigating novel therapies for lymphoma patients. His practice team includes Anna Morrison, R.N., and Kerri Hugelmaier, N.P., providing comprehensive care for lymphoma patients. Dr. Friedberg has established the Lymphoma Epidemiology of Outcomes (LEO) Consortium, a large observational cohort study supporting broad research on NHL prognosis and survivorship. His leadership extends to national organizations where he contributes to developing clinical practice guidelines and consensus recommendations for lymphoma treatment.

Kristian HelinView profile

Professor

• Cancer biology
• Epigenetics
• Stem cells
• +5 more

Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.

Britt AdamsonView profile

Associate Professor

• Stress Response Networks
• DNA Damage Response
• Genome Editing
• +3 more

Britt Adamson is an Associate Professor in the Department of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics at Princeton University, where she serves as Director of the Undergraduate Program in Quantitative and Computational Biology. Her lab investigates molecular networks in human cells with focus on stress response mechanisms and genome editing technologies. She received her B.S. in Biology from the Massachusetts Institute of Technology (2005) and Ph.D. in Genetics and Genomics from Harvard University (2012), followed by postdoctoral training at UCSF under Jonathan Weissman supported by a Damon Runyon Cancer Research Foundation Fellowship. Adamson's research centers on how cells organize stress response networks during DNA damage and endoplasmic reticulum stress, developing CRISPR-based functional genomics and single-cell sequencing tools to map molecular behaviors. Her work bridges fundamental cell biology with therapeutic applications in genome editing. Analysis of her 15 most recent publications reveals dominant themes in precision genome editing (prime/base editing optimization) and systematic dissection of DNA repair pathways through combinatorial CRISPR screening. Her lab consistently integrates computational approaches with high-resolution experimental techniques to uncover context-dependent cellular behaviors. Her scientific recognitions include: Damon Runyon Cancer Research Foundation Postdoctoral Fellowship Princeton IP Accelerator Award (2025) STAT Who to Know: 10 Scientists leading a new generation of gene editors (2024) Adamson actively mentors eight graduate students (including alumni Ann Cirincione and Jun Hussmann) and two postdocs, with research funded through institutional awards and collaborative grants. Her lab's technological developments have enabled projects spanning virology, immunology, and developmental biology. The Adamson Lab operates within Princeton's Lewis-Sigler Institute for Integrative Genomics, fostering an interdisciplinary environment that merges cell biology, genomics, and computational science. Current projects focus on improving prime editing efficiency and understanding stress response adaptation in disease contexts.

Naresh R. ShanbhagView profile

Professor

• Energy-efficient computing
• Machine learning hardware
• In-memory computing
• +7 more

Naresh R. Shanbhag is the Jack Kilby Professor in the Department of Electrical and Computer Engineering and the Coordinated Science Laboratory at the University of Illinois at Urbana-Champaign. He serves as Director of the Systems on Nanoscale Information fabriCs (SONIC) Center and held the D.J. Gandhi Distinguished Visiting Professorship at IIT Mumbai from 2015-2020. Previously, he was a visiting faculty member at National Taiwan University (2007) and Stanford University (2014). Dr. Shanbhag received his doctorate from the University of Minnesota (1993) in Electrical Engineering. From 1993 to 1995, he worked at AT&T Bell Laboratories as the lead chip architect for AT&T's 51.84 Mb/s transceiver chips over twisted-pair wiring for Asynchronous Transfer Mode (ATM)-LAN and very high-speed digital subscriber line (VDSL) chip-sets. His research focuses on the design of energy-efficient machine learning, communications, and signal processing systems on resource-constrained embedded platforms. He explores fundamental trade-offs between energy efficiency, latency and accuracy of decision-making systems implemented in nanoscale technologies, with applications to computer vision, biomedicine, automatic target recognition, and imaging. His work spans four primary focus areas: Resource-efficient Machine Learning for the Edge, In-memory Computing (IMC), Energy-efficient High Data Rate Communications, and Shannon-inspired Statistical Error Compensation (SEC). Analysis of his recent publications reveals a strong emphasis on in-memory computing architectures (SRAM, MRAM, RRAM) for machine learning acceleration. His work consistently addresses energy-accuracy trade-offs, with increasing attention to security aspects of hardware implementations and applications to MIMO signal processing and edge AI systems. His research demonstrates a progression from theoretical foundations to practical silicon implementations. 2024 Semiconductor Research Corporation Innovation Award 2018 Semiconductor Industry Association/Semiconductor Research Corporation University Researcher Award 2018 IEEE International Symposium on Circuits and Systems Best Paper Award 2006 IEEE Fellow 1996 National Science Foundation CAREER Award Professor Shanbhag has mentored over 50 graduate students who now work at leading technology companies including Qualcomm, Amazon, Nvidia, Intel, and Apple. His research has been generously supported by the National Science Foundation, DARPA, AFRL, Semiconductor Research Corporation, Texas Instruments, Sandia National Laboratories, and industry partners including IBM, GlobalFoundries, and Intel Corporation. He led the Alternative Computational Models research theme (2006-2012) and was the founding Director of the SONIC Center (2013-2017), a 5-year multi-university center funded by DARPA and SRC. Currently, he leads research themes in the SRC and DARPA funded JUMP 2.0 Program's Center for Co-Design of Cognitive Systems and the Center for Ubiquitous Connectivity, and in the NSF IUCRC Center for Advanced Semiconductor Chips with Accelerated Performance (ASAP). As Director of the Systems on Nanoscale Information fabriCs (SONIC) Center, Professor Shanbhag leads a multidisciplinary team exploring novel computing paradigms for the nanoscale era. His group has benchmarked an extensive collection of in-memory computing and digital accelerator IC designs, maintaining a publicly available IMC benchmarking repository of metrics extracted from published IC prototypes. His research philosophy integrates concepts from information theory, statistical signal processing, detection and estimation, VLSI architectures, and digital and analog integrated circuits to develop energy-efficient systems from algorithms to silicon implementations.

• Cellular Toxicology
• In Vitro Methodology
• Fish Cell Biology
• +2 more

Dr. Vivian Dayeh is an Associate Professor in the Department of Biology at the University of Waterloo, where she joined in 2004 as a full-time lecturer. Her roles include Teaching Fellow, Undergrad Advisor for Biomedical Science and Medical Physiology, and coordinator of the Biotech Technician Diploma program. Ph.D. Biology, University of Waterloo (2004) M.Sc. Biology, University of Waterloo (2001) B.Sc. Biology, University of Waterloo (1999) Dr. Dayeh specializes in cellular toxicology and in vitro methodology development , focusing on alternatives to whole-organism testing in aquatic environments. Her work explores toxicant effects on fish cells, particularly gill and intestinal epithelial systems, and employs protozoa as toxicity indicators. Recent research examines temperature and nutritional stress impacts on cell viability. Her publications from 2004-2025 demonstrate expertise in fish cell culture , cytotoxicity assays , and environmental contaminant testing , with applications in regulatory toxicology and industrial effluent analysis. 2024 Service Award, Society for In Vitro Biology 2021 Fellow Award, Society for In Vitro Biology Multiple Outstanding Performance Awards (2006-2020) Jack Carlson Teaching Excellence Awards (2006, 2018) Joseph F. Morgan Awards (2002, 2003) As an educator, Dr. Dayeh teaches core courses including Introductory Cell Biology , Human Anatomy , Human Physiology , Environmental Toxicology , and Animal Cell Biotechnology . She serves on the SIVB Board and facilitates instructional skills workshops.

Steven L'HernaultView profile

Professor

• Spermatogenesis
• Cell Biology
• Genetics
• +2 more

Steven L'Hernault is Professor and Chairman of Biology at Emory University, where he leads research on cellular and developmental processes using Caenorhabditis elegans models. His laboratory investigates molecular mechanisms underlying spermatogenesis, focusing on genetic controls of sperm development and function. The L'Hernault Lab studies highly conserved genome protection mechanisms in germ lines using genetic, molecular, and biochemical approaches. Key research areas include secretory vesicle function, membrane protein interactions, and ubiquitin ligase activity during sperm differentiation. Recent publications examine paternal epigenetic inheritance pathways and palmitoyltransferase functions in spermiogenesis. The lab maintains an extensive collection of C. elegans mutants with defective spermatogenesis to study fundamental cellular processes.

• Neurovascular Surgery
• Cerebrovascular Disorders
• Stroke Intervention
• +3 more

Ryan M Hebert, MD, is an Assistant Professor of Neurosurgery at the Yale School of Medicine, affiliated with the Neurosurgery department. He specializes in neurovascular disorders, including open and endovascular treatments for intracranial aneurysms, arteriovenous malformations, carotid disease, and dural arteriovenous fistulas. He also focuses on interventions for ischemic and hemorrhagic strokes. His practice locations include Yale New Haven Hospital and Lawrence and Memorial Hospitals in Connecticut. Education & Training: Bachelor’s in Molecular, Cellular, and Developmental Biology from the University of Colorado – Boulder (Howard Hughes Undergraduate Research Grant recipient) MD from Yale School of Medicine (NIH-funded thesis on CCM3 in cerebral cavernous malformations) 7-year Neurosurgery Residency at Yale New Haven Hospital, including enfolded neuro-interventional training CAST-accredited fellowship in Endovascular Neurosurgery and Neurovascular Critical Care at Thomas Jefferson University Hospital (2016) Research Interests: Dr. Hebert’s work centers on emerging surgical and endovascular techniques for neurovascular disorders, risk stratification in carotid disease, vasospasm prediction/post-subarachnoid hemorrhage treatment, and outcomes of minimally invasive spine surgery. His studies often integrate clinical practice with translational research, emphasizing patient outcomes and procedural optimization. Key topics include flow diverters, cranial nerve palsies, hospital frailty risk scores, and immune mechanisms driving aneurysm rupture. Publications Trends: His recent articles emphasize clinical outcomes of endovascular procedures, stroke interventions, and immune mechanisms in aneurysm rupture. He frequently collaborates on meta-analyses and systematic reviews to evaluate treatment efficacy and complication rates, particularly involving cranial nerve recovery and thrombectomy volumes. Awards & Grants: He secured an NIH-funded thesis and a Howard Hughes Undergraduate research grant. No explicit scientific awards are listed, but his work has been recognized via peer-reviewed publications and contributions to clinical guidelines. Advising & Grants: While no students are listed, he collaborates with prominent researchers like Charles Matouk, Kevin Sheth, and Joseph Antonios on NIH-funded projects. His research addresses healthcare resource utilization and procedural volume impacts on mortality, indicating a focus on translational and clinical studies. Labs & Teams: Active in interdisciplinary teams at Yale School of Medicine, particularly in neurovascular critical care and endovascular surgery. Collaborates with the Stroke Center and Janeway Society for physician-scientist development.

• Stem Cell Biology
• Genetic Engineering
• Epigenetics
• +5 more

Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.

John A. Copland, IIIView profile

Professor

• Cancer Biology
• Molecular Carcinogenesis
• Translational Research
• +3 more

Dr. John A. Copland III is a Professor of Cancer Biology and Biochemistry & Molecular Biology at Mayo Clinic in Jacksonville, Florida. He leads the Cancer Biology and Translational Research Laboratory, focusing on molecular mechanisms of carcinogenesis, tumor progression, and development of targeted cancer therapies. Education: PhD in Physiology & Endocrinology (Medical College of Georgia), MS in Endocrinology (Medical College of Georgia), BS in Chemistry (Columbus College), with postdoctoral training at University of Texas Medical Branch. Research interests center on: Identifying tumor suppressor genes (e.g., RhoB, TBR3, GATA3) and oncogenes (e.g., FOXO3a, SCD1, NPTX2). Developing patient-derived xenografts and live cell models for personalized medicine. Designing SCD1 inhibitors via in silico modeling for clinical trials. Recent publications highlight his work on SCD1 inhibition in leukemia and thyroid cancer ImmunoPET imaging of thyroid tumors CRISPR-identified drug synergies in cholangiocarcinoma Patient-specific combination therapies using xenograft models

Ali ManiView profile

Associate Professor

• Fluid Mechanics
• Turbulence Modeling
• Numerical Simulations
• +3 more

Ali Mani is an Associate Professor of Mechanical Engineering at Stanford University and a faculty affiliate at the Institute for Computational and Mathematical Engineering. He earned his PhD in Mechanical Engineering from Stanford in 2009, following an M.S. (2004) and B.S. (2002) from Stanford and Sharif University of Technology, respectively. His research focuses on fluid mechanics, turbulence, and numerical simulations, with applications in multiphase flows, electrokinetic systems, and applied mathematics. His group develops high-fidelity simulation tools and reduced-order models to understand transport processes in turbulent and chaotic systems. Research interests include turbulence modeling, two-phase flow dynamics, and electrochemical transport. Recent work explores eddy viscosity operators, nonlocal transport phenomena, and computational methods for multiphase systems. The group's studies often bridge experimental validation and numerical analysis to improve predictive engineering models. Key contributions span electrokinetic transport in porous media, superhydrophobic surface slip effects, and phase field modeling. His lab’s work is supported by grants focusing on fluid dynamics, renewable energy systems, and advanced simulation frameworks.

Joseph P. BresslerView profile

Associate Professor

• Neurotoxicology
• Environmental Health Sciences
• Metal Transporters
• +12 more

Joseph P. Bressler is an Associate Professor at Johns Hopkins University, jointly affiliated with the Bloomberg School of Public Health and the Krieger School of Arts and Sciences. He is a member of the Department of Environmental Health and Engineering and conducts research at the Kennedy Krieger Institute in Baltimore, Maryland. His work bridges public health, neuroscience, and molecular toxicology, focusing on environmental impacts on brain development. Education: PhD, Rutgers University, 1978 Dr. Bressler’s research centers on neurotoxicology, particularly how environmental pollutants such as lead, cadmium, and aluminum disrupt metal transport systems and affect neurodevelopment. His laboratory investigates the role of iron and other metal transporters at the blood-brain barrier and in glial cells, revealing mechanisms of metal uptake and toxicity. His work has implications for understanding autism, fetal alcohol syndrome, and other neurodevelopmental disorders. His recent publications highlight ongoing research into metal homeostasis, cytotoxicity in cancer and neuronal cell lines, e-cigarette aerosol variability, and epigenetic changes in sex chromosome aneuploidies. The research spans molecular mechanisms, in vitro models, and human health outcomes, demonstrating a multidisciplinary approach to environmental health. Scientific Contributions: Elucidated how lead and cadmium hijack iron transporters to enter the brain Demonstrated aluminum activation of iron uptake pathways in glial cells Investigated flavoring agents like ethyl maltol in enhancing metal toxicity Explored epigenetic and behavioral impacts in rare genetic conditions Dr. Bressler has advised numerous researchers and collaborators across disciplines. His work has been supported by federal and institutional grants, though specific funding details are not provided in the source text. He actively publishes in high-impact toxicology and environmental health journals, with research cited in policy and public health discussions. He leads a research laboratory focused on cellular and molecular mechanisms of neurotoxicity, utilizing in vitro models of the blood-brain barrier, astrocytes, and neuronal cell lines. His team collaborates widely across neuroscience, public health, and environmental engineering domains.

Raphael FranziniView profile

Associate Professor

• Drug Discovery
• Medicinal Chemistry
• Bioorthogonal Chemistry
• +3 more

Raphael Franzini serves as Associate Professor of Medicinal Chemistry at the University of Utah, actively contributing to the Biological Chemistry PhD Program. His research pioneers innovative chemical approaches for therapeutic development, with dual focus on DNA-encoded library technologies and bioorthogonal drug delivery systems. His educational foundation includes an M.S. from the Swiss Federal Institute of Technology (Lausanne) and a Ph.D. from Stanford University. This training underpins his group's multidisciplinary methodology combining organic synthesis, bioconjugation, computational modeling, and advanced imaging techniques. Dr. Franzini's research program centers on two transformative areas: First, advancing DNA-encoded library screening through computational integration to identify leads for challenging targets like Tankyrase and Sirtuin 6, with recent work addressing false negatives in machine learning prediction. Second, developing novel bioorthogonal release chemistry using isonitrile-tetrazine reactions for spatiotemporally controlled drug activation, validated in zebrafish models. His group emphasizes both technological innovation and therapeutic translation, with chemistry designed to minimize off-target effects in solid tumors. Analysis of his 15 most recent publications reveals escalating integration of computational methods with experimental library screening, alongside refinement of bioorthogonal release kinetics. The work spans chemical biology, medicinal chemistry, and pharmaceutical sciences, with growing emphasis on machine learning for library data interpretation and in vivo validation of drug-release systems. Dr. Franzini maintains an active research laboratory that provides comprehensive training in cutting-edge drug discovery methodologies. His group culture prioritizes both scientific innovation and researcher development, with projects spanning from fundamental reaction kinetics to therapeutic applications. The lab's infrastructure supports organic synthesis, molecular imaging, and computational analysis for advancing precision therapeutics.

Zeyad IbrahimView profile

Researcher

• Pharmacogenomics
• Cancer Treatment
• Pediatric Oncology
• +3 more

Zeyad Ibrahim is a Doctor of Philosophy student at the University of Western Australia, engaged in Casual Teaching and acting as a Multi-Discipline Contractor/Visitor. Affiliated with the School of Allied Health, UWA Medical School, and the UWA Centre for Medical Research (affiliated with the Harry Perkins Institute of Medical Research), he focuses on pharmacogenomics in pediatric cancer treatment. Education: Doctor of Philosophy, School of Allied Health, University of Western Australia. Research interests include methotrexate pharmacogenomics, CRISPR/Cas9 genomic models for drug efficacy assessment, and systematic reviews addressing gaps in pediatric cancer therapies. His work aligns with UN Sustainable Development Goals related to health and well-being. Publications include two peer-reviewed abstracts in the Asia-Pacific Journal of Clinical Oncology (2019), exploring methotrexate pharmacogenomics in pediatric cancers and a CRISPR-based genomic model. He received the Churchill Fellowship 2022 for pharmacogenomics research. Grants: Co-investigator on two major projects funded by the Western Australian Department of Health, focusing on personalized cancer treatment using pharmacogenomics to improve outcomes and reduce costs for seriously ill children (MiSSK initiative). Labs/Teams: Involved with the Centre for Optimisation of Medicines and collaborates with the Harry Perkins Institute of Medical Research.

Mustafa YavuzView profile

Professor

• Opto-Nano and Micro-Electro-Mechanical Systems (O-N/MEMS)
• Quantum Electronic Solids
• Superconductors
• +7 more

Mustafa Yavuz is a Professor and Director of the Nano and Micro Systems Lab (NMSL) at the University of Waterloo, Canada, affiliated with Mechanical & Mechatronics Engineering, System Design Engineering, and Electrical & Computer Engineering. He holds cross-appointments in multiple departments and has been a faculty member since 2009. His research focuses on Opto-Nano/MEMS devices, quantum electronic solids, graphene, and superconductors. Yavuz has supervised over 28 graduate students and postdoctoral fellows, leading to impactful contributions in sensors, nanomaterials, and energy harvesting. He has authored/co-authored numerous articles and holds patents in MEMS and nanotechnology. His awards include the University of Waterloo Research Excellence Award (2018) and international fellowships from MINATEC and JSPS. Education: Ph.D. Materials Engineering (University of Wollongong, 1996) Ph.D. Applied Physics (University of Wollongong, 1995) M.Sc. Materials Engineering (Middle East Technical University, 1991) B.Sc. Materials Engineering (Middle East Technical University, 1989) Research Interests: Yavuz specializes in advanced materials and MEMS/NEMS technologies, including opto-nano-MEMS devices, quantum electronic solids (superconductors, graphene), and functional nanomaterials for sensors and energy systems. His work integrates fabrication, packaging, and reliability testing of nanoscale devices for applications in photonics, biomedical sensing, and environmental monitoring. Recent trends in his articles highlight innovations in resonant MEMS mirrors, graphene-based biosensors, and laser-functionalized 2D materials. Scientific Awards: MINATEC Fellowship (2019) Waterloo Engineering Research Excellence Award (2018) International Nanoarchitectonics Fellowship (2017) JSPS Fellowship (2007) Advising & Grants: Yavuz has supervised 26 doctoral students and 28 postdoctoral researchers. His labs, including the NMSL and BioGraph Sense Inc., focus on MEMS packaging, nanojoining, and plasmonic biosensors. He has led projects funded by NSERC, CFI, and industry collaborations with companies like Apple, Samsung, and Smarter Alloys. Labs/Teams: Director of the Nano and Micro Systems Lab (NMSL), co-founder of BioGraph Sense Inc., and collaborator in the Waterloo Institute for Nanotechnology (WIN). His research group develops cutting-edge nanoscale devices with applications in healthcare, energy, and environmental sensing.

Donald RioView profile

Professor

• Nucleic Acid Transactions
• Transposable Elements
• RNA Binding Proteins
• +3 more

Donald Rio holds the Richard and Rhoda Goldman Distinguished Chair in the Biological Sciences and is a Professor of Biochemistry, Biophysics, and Structural Biology. He is affiliated with the Division of Biochemistry and Molecular Biology and the Center for Integrative Genetics. His lab focuses on nucleic acid transactions, including transposable element mobilization (P elements) and RNA binding protein mechanisms controlling alternative splicing. Research highlights include studies on THAP9 proteins in humans/zebrafish, cryo-EM structural analysis of transposase-DNA complexes, and splicing regulation in neurodegenerative diseases like ALS and Parkinson’s. His work combines biochemical, genetic, and computational approaches, including the development of the Junction Usage Model (JUM) for splicing analysis. Research interests span transposition mechanisms linked to HIV integration, immune system recombination, and evolutionary genome dynamics. His team investigates how RNA binding proteins like hnRNPA1 influence splicing in disease contexts, with projects involving CRISPR-based models and patient RNA-seq data analysis. Collaborations include studies on splicing accuracy across tissues and age, and the impact of splicing defects in neurodegenerative disorders. Key awards include the Goldman Chair. His lab’s contributions bridge fundamental molecular mechanisms with translational applications in genetic disease modeling and drug discovery. Recent work focuses on isogenic stem cell models (iSCORE-PD) for Parkinson’s research and structural biology insights into transposase function. Grants and projects involve NIH funding for ALS splicing studies and collaborations with institutions like the Buck Institute. His lab actively publishes in top journals such as Genome Research , PNAS , and Nature , with a strong emphasis on cryo-EM and bioinformatic methods.